GlassScriptPhysician profile
Jacob M Aftel
NPI 1801884598
$1,358.76
in general payments reported to CMS, 2019-2025
13 companies · $383 in 2025
The $383 reported for 2025 was more than what 89% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.65 · 2020: $16.82 · 2022: $40.15 · 2023: $212 · 2024: $650 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214 · Education: $32.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.90 |
| Education | $32.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $640.87 | 2023-2025 | Entyvio, Eohilia |
| Celgene Corporation | $129.02 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $116.20 | 2022-2024 | Ocaliva |
| Janssen Biotech, INC. | $106.70 | 2023-2025 | Stelara, Tremfya, Remicade |
| Ardelyx, INC. | $87.46 | 2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.41 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $46.72 | 2024 | Omvoh |
| Qol Medical, LLC | $45.46 | 2023 | Sucraid |
| Celltrion USA INC. | $32.24 | 2024 | Zymfentra |
| Genzyme Corporation | $23.83 | 2025 | |
| Abbvie INC. | $22.22 | 2025 | |
| Ucb, INC. | $16.86 | 2019 | |
| Braintree Laboratories, INC. | $15.77 | 2025 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Aftel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.